Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies.
about
Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage.Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control studySecondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis.Impact of previous invasive pulmonary aspergillosis on the outcome of allogeneic hematopoietic stem cell transplantation.Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.Managing fungal and viral infections in pediatric leukemia.Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature.Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.Epidemiology of invasive fungal diseases on the basis of autopsy reports.Treatment principles for the management of mold infections.Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.A long-term survivor of disseminated Aspergillus and mucorales infection: an instructive case.Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients.Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.Retrospective assessment of secondary prophylaxis for invasive aspergillosis in neutropenic hematology patients and identification of risk factors for relapse of fungal disease.Invasive coinfection with Aspergillus and Mucor in a patient with acute myeloid leukemia.Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.Invasive Fungal Infections: A Continuing Challenge Report from the 17th International Symposium on Infections in the Immunocompromised Host, Genoa, Italy, 24–27 July 2012
P2860
Q33573641-17E4B58C-395D-4125-B3C9-231704D6574FQ34166590-1715586E-D3EA-4F03-BEE6-F4E5C9D5263CQ34532546-C398043C-190B-4D1F-83BA-CB60661AC8B8Q34543097-E770DEA5-117A-41A9-8FDB-E1A4DAD06DE4Q34756973-3756D520-F01C-4492-B72F-B45637DD12B5Q35672258-072C17E0-73D0-4586-8544-FD0DF7E49A96Q36046991-07634CCB-8D27-46E3-A26A-C10CBD4F8BEBQ36264982-3FAEEA3A-03AB-446C-A342-F0425C69798CQ36513778-70B5A965-BA78-482D-A5D3-F2DADFB3CA74Q36867435-564D8297-C40E-43D3-B5F2-B47A2AED338BQ37442798-37E60BE7-B5FE-450E-A602-F86AEB6171A4Q37810281-00797320-DF02-427D-A12C-0F5019135B7EQ37863923-E997BB43-6895-4938-A5A3-81849559DD88Q37935599-7C1CE965-F958-46A4-B1D3-E4A81A78BE18Q38262508-3CE2A8E5-CB8E-4116-ADB8-563906F9DBA2Q38265845-F6FDA6ED-978F-45E9-BE1B-3AEFE9707356Q40360694-9E15CA11-63A0-4EC4-AF2F-7566BBB596E0Q42203400-D145F8BE-DDBA-4B3F-A702-4E167EC55339Q42586750-D4D637F9-9EB9-458B-AB91-5CB30B570399Q42970799-98206901-2FCB-4317-9606-C6C6F3D58548Q44636050-6C97709E-E0C4-4805-9B0E-C4585058608DQ46729472-FF55E5C2-E249-4140-9F2A-9BE3F79342C6Q51169948-E2BDF6A2-FEF4-4F0E-9CB2-B8DF9747C2F6Q52746966-676BD2BC-DBE3-48BA-AB7D-8C0EB1403AE7Q57746142-B5B26CD7-9464-4B8E-A490-B8E13097388B
P2860
Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Clinical issues regarding rela ...... th hematological malignancies.
@ast
Clinical issues regarding rela ...... th hematological malignancies.
@en
type
label
Clinical issues regarding rela ...... th hematological malignancies.
@ast
Clinical issues regarding rela ...... th hematological malignancies.
@en
prefLabel
Clinical issues regarding rela ...... th hematological malignancies.
@ast
Clinical issues regarding rela ...... th hematological malignancies.
@en
P356
P1476
Clinical issues regarding rela ...... th hematological malignancies.
@en
P2093
Dimitrios P Kontoyiannis
Nikolaos V Sipsas
P304
P356
10.1086/503844
P407
P577
2006-04-24T00:00:00Z